drugset / Trial / NCT00088166
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Phase 3
Completed
200 enrolled
Celtic Pharma Development Services
Neurobiological Technologies · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.
Timeline
- Start
- 2004-05
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xerecept | Unknown | 1 mg | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | — |